HLK-R033

HLK-R033 is an investigational drug candidate being developed by Pharmacin International (also known as HLK Pharmacin or Shenzhen Pharmacin) for the treatment of inflammatory bowel disease (IBD). The candidate is being developed via the FDA's 505(b)(2) regulatory pathway, which involves the reformulation or repurposing of a previously approved active pharmaceutical ingredient. By utilizing this pathway, the developer aims to improve the therapeutic profile of an existing IBD treatment, potentially enhancing efficacy, safety, or patient compliance through a new delivery method or formulation. As of early 2024, HLK-R033 is in the feasibility and early development stage, and the specific identity of the active ingredient has not been publicly disclosed.